News
ChromaDex to Report First Quarter 2020 Financial Results on Monday, May 11, 2020
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Mon., May 11, 2020 at 4:30 p.m. ET to discuss its financial results for the first quarter ended Mar. 31, 2020. The financial results will be reported in a press release after...
Cellular Health Market Leader Tru Niagen® to Launch in U.K. Online and in Retail Stores Exclusively with Superdrug, Expanding Global Retail Partnership Between ChromaDex and A.S. Watson Group
ChromaDex announces exclusive retail partnership with Superdrug UK, entering the European market and driving global expansion of Tru Niagen® LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its partnership with A.S. Watson Group into...
ChromaDex and Watsons Launch New Tru Niagen® Beauty Cellular Nutrient in Hong Kong, Broadening Global Retail Partnership
ChromaDex and A.S. Watson Group launch new Tru Niagen® Beauty in Watsons Hong Kong stores and online LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its new Tru Niagen® Beauty cellular health and beauty daily supplement...
ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR)
Preclinical research from Dr. Charles Brenner and a team of leading scientists from three US universities concludes that key steps in coronavirus infection and innate immunity involve a tug-of-war with cellular NAD LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global...
Cellular Health Market Leader Tru Niagen® Launches Online in Australia
ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia LOS ANGELES, March 23, 2020 -- ChromaDex Corp. (NASDAQ:CDXC) announced today the e-commerce launch of Tru Niagen® in Australia with distribution partner Matakana Health Limited...
ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19
LOS ANGELES, March 12, 2020 -- ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client, implying unsupported health claims about Tru Niagen and COVID-19. There are no published...
CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS
Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018 Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing efficiency year-over-year.Tru Niagen® net sales of $10.2 million, a 57% increase year-over-year.Net loss...
New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model
Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal modelsLOS ANGELES, Feb. 27, 2020 -- ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine...
ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020
LOS ANGELES, Feb. 25, 2020 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Mar. 10, 2020 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended Dec. 31, 2019. The financial results will be reported in a...
ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health Science
Tru Niagen® to launch in Persona's customized vitamin and nutritional supplement delivery serviceLOS ANGELES, Feb. 12, 2020 -- ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of its flagship cellular health supplement Tru Niagen® (nicotinamide...